mavrilimumab
Jump to navigation
Jump to search
Indications
- investigational drug for
Dosage
IV administration, doses of up to 100 mg Mecahism of action:
More general terms
Additional terms
References
- ↑ De Luca G, Cavalli G, Campochiaro C et al GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatology. 2020 Aug;2(8):e465-e473 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32835256 PMCID: PMC7430344 Free PMC article https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30170-3/fulltext
- ↑ Wikipedia: Mavrilimumab https://en.wikipedia.org/wiki/Mavrilimumab